Adjei George O, Goka Bamenla Q, Binka Fred, Kurtzhals Jorgen Al
Center for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, College of Health Sciences, PO Box 4236, Accra, Ghana.
Expert Rev Anti Infect Ther. 2009 Aug;7(6):669-81. doi: 10.1586/eri.09.53.
Artemether-lumefantrine (AL; Coartem, Riamet) is the first fixed-dose artemisinin combination therapy (ACT) regimen to be manufactured under Good Manufacturing Practice conditions, and is the most widely adopted ACT regimen used in malaria control programs. AL is approved for the treatment of uncomplicated malaria in adults, children and infants, and as treatment of uncomplicated malaria in nonimmune travelers returning from malarious areas. AL is efficacious for treating uncomplicated malaria in children and the frequency of associated adverse events is not higher than other available ACT regimens. In this review, available evidence on efficacy and safety of AL in the treatment of uncomplicated malaria, with emphasis on children where appropriate, and focusing on characteristics that are potentially important for malaria control policy decisions, are presented and discussed.
蒿甲醚-本芴醇（AL；科泰复、力复平）是首个在良好生产规范条件下生产的固定剂量青蒿素联合疗法（ACT）方案，也是疟疾防控项目中应用最广泛的ACT方案。AL被批准用于治疗成人、儿童及婴儿的非复杂性疟疾，以及用于治疗从疟疾流行地区返回的非免疫旅行者的非复杂性疟疾。AL在治疗儿童非复杂性疟疾方面疗效显著，且相关不良事件的发生率不高于其他现有的ACT方案。在本综述中，我们展示并讨论了关于AL治疗非复杂性疟疾的疗效和安全性的现有证据，重点关注了儿童群体，并着重探讨了对疟疾防控政策决策可能具有重要意义的特征。
